Contact

Get in touch

Dymista^®^ a novel formulation

Dymista^®^ a novel formulation

Dymista® is a novel intranasal formulation of fluticasone propionate and azelastine hydrochloride.1,2
The recommended daily dose is one spray in each nostril twice a day (morning and evening).2
More effective than current first line therapy in reducing both nasal and ocular symptoms.1.3

  1. Meltzer et al. Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis.
    Int Arch Allergy Immunol 2013;161:369–37.
  2. Dymista SPC 2013.
  3. Price P, Bousquet J, Hellings P, et al. Abstract presented at SERIN, Leuven, Belgium, 21-23 March 2013.

Dymista® is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine of glucocorticoid is not considered sufficient.1

Current therapy is insufficient for most patients since they continue to experience symptoms when treated (even with multiple therapies).2.3

  1. Dymista SPC 2013.
  2. Bousquet PJ, Demoly P, Devillier P, et al. Int Arch Allergy Immunol 2013;160(4):393-400.
  3. Price D, Bousquet J, Pitman R, et al. Abstract presented at EAACI, Milan, Italy, 22-26 June 2013.